Following LXR activation, a decrease in amyloidogenic APP processing and Aβ secretion has been demonstrated in vitro and in AD mouse models, and improvement of cognitive deficits has been observed in AD mice [69, 70]. This evidence concerns the gene APP and Alzheimer disease.